Research progress of lncRNA in chronic myeloid leukemia
Chronic myeloid leukemia(CML)is a myeloproliferative neoplasm caused by BCR-ABL fusion.Although tyrosine kinase inhibitors can effectively inhibit BCR-ABL activity,drug resistance is still a major problem in treatment.Long non-coding RNA(lncRNA)is a kind of ncRNA with a length of more than 200 nucleotides,lncRNAs play important roles in the initiation,development,and drug resistance of CML.In recent years,studies have found that lncRNAs affect the proliferation,apoptosis and drug sensitivity of CML cells by various mechanisms such as interacting with miRNA to regulate downstream signaling pathways,or affecting epigenetic modification,so lncRNAs are potential drug targets of CML.Meanwhile accumulating studies have proved that lncRNA is an effective diagnostic and prognostic biomarker of CML.For instance,HOX transcript antisense RNA(HOTAIR)can be applied to the early diagnosis of CML,and the change of prostate cancer antigen 3(PCA3)expression level can be used as a prognostic indicator of CML.In this review,the mechanism of CML-related lncRNA,its relationship with CML clinical stage,drug resistance and prognosis,as well as its research progress as diagnostic and prognostic biomarkers and drug targets were summarized.
long non-coding RNAchronic myeloid leukemiabiomarkersdrug targets
NETL
NSTL
万方数据
